Jazz Pharmaceuticals (JAZZ) Stock Analysis — November 2026

Jazz Pharmaceuticals (JAZZ) stock is currently trading at $234.66 per share on the NASDAQ exchange. This represents a daily gain of +2.14% ($4.92) from the previous closing price of $229.74. Over the past 52 weeks, JAZZ has traded between a low of $128.80 and a high of $266.38, placing the current price at approximately -12% from its annual high. The stock has a market capitalization of $14.90B, making it one of the larger cannabis companies tracked by Cannabismarketcap. Jazz Pharmaceuticals operates in the Biotech sector, classified under "PHARMACEUTICAL PREPARATIONS", serving the broader cannabis industry.

Jazz Pharmaceuticals (JAZZ) has a current market capitalization of $14.90B, calculated by multiplying its 64.2M shares outstanding by the current stock price of $234.66. Market capitalization is a key measure of a company's total equity value as perceived by the public market, and it places Jazz Pharmaceuticals among the large-cap cannabis companies tracked on Cannabismarketcap. For context, the enterprise value (market cap plus debt minus cash) stands at $18.43B, which accounts for the company's balance sheet structure. Investors often use market cap alongside revenue and profitability metrics to assess relative valuation within the cannabis sector.

Jazz Pharmaceuticals (JAZZ) reports trailing twelve month (TTM) revenue of $4.72B, reflecting the total sales generated by the company over the most recent four quarters. Revenue has changed +13.48% year-over-year, indicating growth momentum relative to the prior period. The current price-to-sales ratio is 3.16x, which means investors are paying $3.16 for every $1 of annual revenue — a moderate valuation in the context of the cannabis sector. Revenue is one of the most closely watched metrics for cannabis companies, as many are still scaling operations in a rapidly evolving regulatory environment. View the full income statement and quarterly revenue breakdown on Cannabismarketcap for detailed trend analysis.

Jazz Pharmaceuticals (JAZZ) reports several important financial metrics that investors track closely. The company has a market capitalization of $14.90B, trailing twelve month revenue of $4.72B. Jazz Pharmaceuticals holds $2.04B in cash and equivalents against $5.57B in total debt. Total debt equals 0.37x market capitalization. The price-to-sales ratio stands at 3.16x, while the enterprise value to revenue multiple is 3.91x. With 64.2M shares outstanding, investors should consider both the fundamental financial performance and share structure when evaluating JAZZ.

Jazz Pharmaceuticals currently employs approximately 2,890 people across its operations. As a cannabis biotech company headquartered in the United States, its workforce supports activities spanning pharmaceutical preparations and related business functions. Based on trailing twelve month revenue of $4.72B, this equates to approximately $1.6M in revenue per employee, which is a useful efficiency metric for comparing operational productivity across cannabis companies. Employee count is an important indicator of a company's operational scale and its capacity for growth in an industry that remains highly labor-intensive due to regulatory requirements.

Jazz Pharmaceuticals trades under the ticker symbol JAZZ on the NASDAQ exchange, and the stock is denominated in US dollars (USD). Shares can typically be purchased through most standard brokerage accounts. The company has been publicly listed since 2007-06-01, giving it a track record in the public markets that investors can analyze for long-term trends. The stock sees average daily trading volume of approximately 898.5K shares, which is an important consideration for liquidity and the ability to enter or exit positions without significant price impact.

Jazz Pharmaceuticals is classified as a cannabis biotech company, meaning it focuses on pharmaceutical and biotechnology applications of cannabinoids, including drug development and clinical research. Its official SIC classification is "PHARMACEUTICAL PREPARATIONS," which provides additional detail about its core business activities. The Biotech sector is a key segment of the cannabis market, and investors often compare companies within the same sector to identify relative outperformers. You can compare JAZZ with other Biotech stocks on Cannabismarketcap's sector page to see how it ranks on metrics like market cap, revenue, and margins.

You can compare Jazz Pharmaceuticals (JAZZ) side-by-side with any cannabis stock on Cannabismarketcap using the dedicated comparison tool. Key comparison metrics include market cap ($14.90B), trailing twelve month revenue ($4.72B), price-to-sales ratio (3.16x). Jazz Pharmaceuticals sits in the Biotech sector, so the most relevant peer comparisons would be against other Biotech companies, though cross-sector comparisons can also reveal interesting insights about relative valuation. Visit the rankings page to see where JAZZ stands across all cannabis companies on metrics like revenue growth (+13.48% YoY), cash position ($2.04B), and employee count (2,890).

Jazz Pharmaceuticals (JAZZ) has traded between a 52-week low of $128.80 and a 52-week high of $266.38, with the current price of $234.66 sitting approximately -12% from the annual high. This range represents a spread of $137.57 (107% from low to high), which reflects the volatility the stock has experienced over the past year. The 52-week range is a commonly used technical indicator that helps investors understand whether a stock is trading near the top or bottom of its recent range, and it can inform decisions about entry and exit points. Cannabis stocks in general tend to exhibit higher volatility than broader market indices due to evolving regulations and market sentiment.

Jazz Pharmaceuticals (JAZZ) is valued at a market capitalization of $14.90B with a price-to-sales ratio of 3.16x, and an enterprise value of $18.43B. The EV/Revenue multiple of 3.91x provides a debt-adjusted view of valuation relative to sales, which is particularly important for comparing companies with different capital structures. In the cannabis industry, valuations can vary significantly depending on sector (MSO, LP, Ancillary, etc.), growth rate, and path to profitability. Jazz Pharmaceuticals's positive revenue growth of +13.48% YoY may justify a premium relative to slower-growing peers. Investors can use the Cannabismarketcap rankings and comparison tools to benchmark JAZZ against specific competitors on valuation multiples, growth rates, and profitability.

Jazz Pharmaceuticals (JAZZ) has an estimated enterprise value (EV) of $18.43B, which is calculated by taking the market capitalization of $14.90B, adding total debt of $5.57B, and subtracting cash and equivalents of $2.04B. Enterprise value is widely considered a more comprehensive measure of a company's total value than market cap alone because it accounts for the capital structure, including debt obligations and available liquidity. The resulting EV/Revenue ratio of 3.91x allows for an apples-to-apples comparison with peers regardless of differences in leverage. For cannabis companies in particular, where balance sheet health varies dramatically, enterprise value provides a more accurate picture of acquisition cost and relative valuation.

Determining whether Jazz Pharmaceuticals (JAZZ) is overvalued or undervalued requires analyzing multiple valuation metrics in context. The current price-to-sales ratio of 3.16x is moderate for the cannabis sector, suggesting the market is pricing in some growth expectations. The stock is currently trading at $234.66, which is -12% from its 52-week high of $266.38, with revenue growth of +13.48% YoY. Investors should consider the company's enterprise value of $18.43B, its cash position of $2.04B, and the broader cannabis industry outlook when forming a valuation opinion. Cannabismarketcap provides all the data needed for a thorough analysis, but this information should not be considered investment advice.

Investing in Jazz Pharmaceuticals (JAZZ) carries several risks that investors should carefully consider. First, the cannabis industry remains federally illegal in the United States, creating regulatory uncertainty that can impact stock prices, banking access, and tax obligations (notably IRC Section 280E). Second, Jazz Pharmaceuticals's balance sheet shows $5.57B in total debt against $2.04B in cash, which investors should monitor for dilution risk or liquidity concerns. Additionally, the stock has shown a 52-week range of $128.80 to $266.38, reflecting meaningful price volatility. As with all cannabis stocks, investors face risks from changing state regulations, competitive pressures, and the evolving legal landscape. This information is for educational purposes only and is not investment advice.

Jazz Pharmaceuticals (JAZZ) holds $2.04B in cash and equivalents on its balance sheet, set against $5.57B in total debt. This gives the company a net debt position of $3.53B. Balance sheet strength is especially important in the cannabis industry, where companies often face limited access to traditional banking and capital markets. Investors should track these metrics over time on Cannabismarketcap to identify trends in cash consumption and debt management.

Jazz Pharmaceuticals (JAZZ) currently has 64.2M shares outstanding, which when multiplied by the current stock price of $234.66 gives the company its market capitalization of $14.90B. Share count is important because all per-share metrics (earnings per share, book value per share, etc.) are directly impacted by changes in shares outstanding. Cannabis companies frequently issue new shares to raise capital, so monitoring dilution trends on Cannabismarketcap is recommended for long-term investors.

Most cannabis companies, including Jazz Pharmaceuticals (JAZZ), do not currently pay dividends. The cannabis industry is still in a growth phase, and companies typically reinvest available capital into expanding operations, securing new licenses, building out retail and cultivation infrastructure, and navigating complex regulatory requirements. Additionally, the IRC Section 280E tax burden significantly reduces the free cash flow available for shareholder distributions. Investors in cannabis stocks should generally expect returns to come from capital appreciation rather than dividend income. If Jazz Pharmaceuticals initiates a dividend in the future, it would be reported in their SEC filings and reflected on Cannabismarketcap.

To research Jazz Pharmaceuticals (JAZZ) before investing, start with the company overview on Cannabismarketcap, which provides current price ($234.66), market cap ($14.90B), and key financial metrics. Next, review the full financial statements page for quarterly revenue trends, margins, and balance sheet details. Check the analyst ratings page for Wall Street consensus and price targets, and the technical analysis page for chart patterns and momentum indicators. Compare JAZZ against sector peers using the comparison tool to understand relative valuation. Review recent news coverage for regulatory developments or corporate events. Finally, read the investment analysis page for a comprehensive deep-dive. Cannabis investing carries unique risks including federal illegality, regulatory uncertainty, and limited banking access — always conduct thorough due diligence before making any investment decision.

Jazz Pharmaceuticals's market capitalization of $14.90B represents the total market value of all its outstanding shares (64.2M shares multiplied by the current stock price of $234.66). Market cap is the primary measure investors use to classify companies by size: large-cap companies (over $1B) like Jazz Pharmaceuticals are generally considered more established with greater liquidity. In the cannabis sector, market cap is especially important because it determines index weighting, institutional investment eligibility, and often correlates with the company's operational scale and geographic reach. Jazz Pharmaceuticals currently ranks # among cannabis stocks tracked on Cannabismarketcap.

Jazz Pharmaceuticals (JAZZ), like all cannabis companies, faces significant regulatory risks that investors should understand. At the federal level, cannabis remains a Schedule I controlled substance in the United States, which restricts banking access, prevents standard business expense deductions under IRC Section 280E, and creates legal uncertainty. Jazz Pharmaceuticals is subject to the evolving regulatory landscape across the jurisdictions where it operates. Potential catalysts include federal rescheduling (which could ease 280E burdens), the SAFE Banking Act (which would improve banking access), and individual state legalization events. Conversely, regulatory setbacks such as license moratoriums, increased enforcement, or unfavorable tax policy changes pose downside risks. Investors should monitor legislative developments closely using Cannabismarketcap's news and legalization tracker.